AUTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Autolus Therapeutics PLC (AUTL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are bearish, its financial performance is weak, and there are no recent positive news catalysts. While analysts maintain a Buy rating with optimistic price targets, the company's financial struggles and lack of significant trading sentiment suggest holding off on investment for now.
The technical indicators for AUTL are bearish. The MACD is negative and expanding downward, RSI is neutral at 32.396, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 1.422, with resistance levels at 1.647 and 1.717.
Analysts see potential in the company's pipeline, particularly its obecabtagene autoleucel product, which could expand into autoimmune diseases. Needham considers the stock undervalued and a strong opportunity for value creation in 2026.
The company has weak financial performance, with declining net income, EPS, and gross margin. No recent news or significant trading sentiment from hedge funds, insiders, or Congress. The stock's technical indicators are bearish.
In Q3 2025, revenue remained flat YoY at $21.19M, net income dropped by -3.63% YoY to -$79.12M, EPS decreased by -3.23% YoY to -0.3, and gross margin significantly worsened to -135.15% YoY.
Analysts maintain a Buy rating with price targets ranging from $8 to $11. They highlight the company's strong pipeline and potential for breakeven by 2028. However, skepticism remains about the company's ability to achieve profitability.
